These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 20513304)

  • 21. Access to syringes in three Russian cities: implications for syringe distribution and coverage.
    Sarang A; Rhodes T; Platt L
    Int J Drug Policy; 2008 Apr; 19 Suppl 1():S25-36. PubMed ID: 18313910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus.
    Kumaranayake L; Vickerman P; Walker D; Samoshkin S; Romantzov V; Emelyanova Z; Zviagin V; Watts C
    Addiction; 2004 Dec; 99(12):1565-76. PubMed ID: 15585048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of harm reduction in Central and Eastern Europe and Central Asia.
    Sarang A; Stuikyte R; Bykov R
    Int J Drug Policy; 2007 Mar; 18(2):129-35. PubMed ID: 17689355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
    Winstock AR; Lea T
    Subst Use Misuse; 2010; 45(1-2):240-52. PubMed ID: 20025451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh?
    Foss AM; Watts CH; Vickerman P; Azim T; Guinness L; Ahmed M; Rodericks A; Jana S
    Addiction; 2007 Jan; 102(1):114-25. PubMed ID: 17207129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Syringe exchanges: a public health response to problem drug use.
    Cox GM; Lawless MC; Cassin SP; Geoghegan TW
    Ir Med J; 2000; 93(5):143-6. PubMed ID: 11072923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Access to sterile syringes for injecting drug users in New York City: politics and perception (1984-2010).
    Heller D; Paone D
    Subst Use Misuse; 2011; 46(2-3):140-9. PubMed ID: 21303234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug use and HIV/AIDS in China.
    Liu Z; Lian Z; Zhao C
    Drug Alcohol Rev; 2006 Mar; 25(2):173-5. PubMed ID: 16627308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increasing prevalence of HIV, and persistent high-risk behaviours among drug users in Bangladesh: need for a comprehensive harm reduction programme.
    Islam MM; Conigrave KM
    Drug Alcohol Rev; 2007 Jul; 26(4):445-54. PubMed ID: 17564883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advocacy for harm reduction in China: a new era dawns.
    Reid G; Aitken C
    Int J Drug Policy; 2009 Jul; 20(4):365-70. PubMed ID: 19097773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
    Hallinan R; Byrne A; Dore GJ
    Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of combination approach on harm reduction programs: the Taiwan experience.
    Lin T; Chen CH; Chou P
    Harm Reduct J; 2016 Jul; 13(1):23. PubMed ID: 27377896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary syringe exchange as a model for HIV prevention programs in the Russian Federation.
    Irwin K; Karchevsky E; Heimer R; Badrieva L
    Subst Use Misuse; 2006; 41(6-7):979-99. PubMed ID: 16809182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Qualitative evaluation of a peer-based needle syringe programme in Vietnam.
    Ngo AD; Schmich L; Higgs P; Fischer A
    Int J Drug Policy; 2009 Mar; 20(2):179-82. PubMed ID: 18242971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug substitution therapy: a new approach in preventing the spread of HIV/AIDS in Malaysia.
    Razali SM
    Trop Doct; 2008 Apr; 38(2):109-10. PubMed ID: 18453507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine.
    Vickerman P; Kumaranayake L; Balakireva O; Guinness L; Artyukh O; Semikop T; Yaremenko O; Watts C
    Sex Transm Dis; 2006 Oct; 33(10 Suppl):S89-102. PubMed ID: 16735956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harm reduction--from a conceptual framework to practical experience: the example of Germany.
    Michels II; Stöver H
    Subst Use Misuse; 2012; 47(8-9):910-22. PubMed ID: 22676562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating national-level syringe availability to injecting drug users and injection coverage: Switzerland, 1996-2006.
    Arnaud S; Jeannin A; Dubois-Arber F
    Int J Drug Policy; 2011 May; 22(3):226-32. PubMed ID: 21600753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clean needles save lives. HIV and injecting drug use.
    James B
    AIDS Action; 1993; (21):4-5. PubMed ID: 12345208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs.
    Li J; Gilmour S; Zhang H; Koyanagi A; Shibuya K
    AIDS; 2012 Oct; 26(16):2069-78. PubMed ID: 22781221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.